Literature DB >> 28562254

Intractable Hypoglycemia in the Setting of Autoimmune Overlap Syndrome.

Kanika Shanker1, Tanicia Daley2, Robert Semple3, Kelly Rouster-Stevens4, J Nina Ham2.   

Abstract

Evaluation of hypoglycemia in a patient with known diabetes mellitus, although usually straightforward, can at times be challenging. We present the case of an 8 year-old Latina girl initially diagnosed with type 1 diabetes mellitus in the setting of multiple autoimmune disorders, including dermatomyositis and lupus nephritis. She subsequently developed signs of insulin resistance and severe hypoglycemia, which was found to be due to insulin-receptor autoantibodies. This condition, known as type B insulin resistance, is a rare, heterogeneous metabolic disease that may feature hypoglycemia in the setting of extreme insulin resistance and hyperinsulinemia and, in this case, masqueraded as type 1 diabetes mellitus. The presence of hypoglycemia in the setting of multiple autoimmune disorders should prompt consideration of autoimmune-mediated hypoglycemia. In addition to immunologic modifying therapies, advances in diabetes care in the form of continuous glucose monitoring have provided an additional tool to manage recurrent hypoglycemia.
Copyright © 2017 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28562254     DOI: 10.1542/peds.2016-0866

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  2 in total

1.  Insulin autoimmune syndrome.

Authors:  Marina Yukina; Nurana Nuralieva; Maksim Solovyev; Ekaterina Troshina; Evgeny Vasilyev
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-06-04

2.  Insulin Autoantibody Syndrome: Varying Clinical Presentations and Response Patterns of an Underrecognized Entity.

Authors:  P R Manjunath; Praveen V Pavithran; Nisha Bhavani; Harish Kumar; Vasantha Nair; Arun S Menon; Usha V Menon; Nithya Abraham; Prem Narayanan; Rony Ruben
Journal:  Indian J Endocrinol Metab       Date:  2019 Sep-Oct
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.